Buscar
Mostrando ítems 11-16 de 16
PD-L1 in systemic immunity: unraveling its contribution to PD-1/PD-L1 blockade immunotherapy
(MDPI, 2020)
info:eu-repo/semantics/article,
The use of monoclonal antibodies targeting PD-1/PD-L1 axis completely changed anticancer treatment strategies. However, despite the significant improvement in overall survival and progression-free survival of patients ...
Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies
(MDPI, 2020)
info:eu-repo/semantics/article,
The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use ...
Systemic CD4 immunity: a powerful clinical biomarker for PD-L1/PD-1 immunotherapy
(EMBO Press, 2020)
info:eu-repo/semantics/article,
The search for non-invasive systemic biomarkers of response to PD-L1/PD-1 blockade immunotherapy is currently a priority in oncoimmunology. In contrast to classical tumor biomarkers, the identification of clinically useful ...
Profound reprogramming towards stemness in pancreatic cancer cells as adaptation to AKT inhibition
(MDPI, 2020)
info:eu-repo/semantics/article,
Cancer cells acquire resistance to cytotoxic therapies targeting major survival pathways by adapting their metabolism. The AKT pathway is a major regulator of human pancreatic adenocarcinoma progression and a key pharmacological ...
Cutting-edge: preclinical and clinical development of the first approved LAG-3 inhibitor
(MDPI, 2022)
Artículo / Artikulua,
Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 (LAG-3) is one of the most important ...
Cutting-edge CAR engineering: beyond T cells
(MDPI, 2022)
Artículo / Artikulua,
Chimeric antigen receptor (CAR)-T adoptive cell therapy is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in haematological malignancies. However, it still lacks ...